The abstract is read at the publisher; the summary is JClub's.
For adolescents and adults with asthma at NAEPP steps 1–2, as-needed-only ICS-SABA or as-needed ICS-formoterol is strongly recommended over SABA-only therapy.
- Why it matters: ICS-containing reliever therapy improves asthma outcomes but is underused, and clinicians need clear, severity-specific guidance balancing exacerbation prevention with minimizing SABA and corticosteroid exposure.
- What they did: An American Thoracic Society guideline panel answered six PICO questions across NAEPP steps 1–5 using systematic literature reviews and GRADE assessments to craft recommendations for reliever strategies.
- The result: Across NAEPP steps 3–5, the panel strongly recommends MART with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA, and conditionally recommends ICS+SABA reliever over SABA reliever for those on scheduled maintenance ICS-LABA.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.